Sort By: Newest first | Oldest first
French pharmacists can now substitute a biosimilar for the prescribed (reference) biological medicine as long as the prescribing physician has not marked the prescription as ‘non-substitutable’.
Patent cliffs remain one of the biggest issues facing the pharmaceutical industry.
In Roche Diagnostics Ltd v Mid Yorkshire Hospitals NHS Trust, an unsuccessful tenderer was entitled to both specific and pre-action disclosure in a public procurement dispute in relation to two related contracts.
This document contains an overview of current rules on access to clinical trials data, an overview of the anticipated legislative changes and a summary of the issues that the new regulation may bring.